Antiretroviral effects of glycerophospholipid stereoisomers of AZT on HIV replication in HT4-6C cells.

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Antiretroviral effects of glycerophospholipid stereoisomers of AZT on HIV replication in HT4-6C cells.

Int Conf AIDS. 1990 Jun 20-23;6(1):186 (abstract no. Th.A.265). Unique Identifier : AIDSLINE ICA6/10026590
Kumar R; Richman DD; Hostetler KY; Vical Inc, San Diego, CA, USA

Abstract: OBJECTIVE: Macrophages are an important target for anti-HIV therapies. We previously reported the synthesis of sn-3 phosphatidylAZT (pAZT), a phospholipid prodrug of azidothymidine (AZT, zidovudine) which was active in HIV-infected cells. pAZT can be targeted to macrophages in vivo. We wished to determine if the sn-1 derivative is also effective in HIV-infected cells since most of the cellular phospholipases are stereospecific for sn-3 phosphoglycerides. METHODS: We synthesized sn-1, sn-3, and racemic dipalmitoylglycerophosphoAZT from the corresponding isopropylidene glycerols by coupling with AZT-monophosphate followed by deblocking and acylation of the hydroxyls of glycerol with palmitic anhydride. Lipid vesicles containing 10 mole % of the pAZTs were incubated with HT4-6C cells after infection with the LAV-1BRU strain of HIV in a plaque reduction assay. RESULTS: sn-3 pAZT reduced plaque formation by 50% (ID50) at 2.1 uM versus 2.2 uM for the sn-1 derivative while racemic pAZT had an IC50 of 2.7 uM. None of these differences were statistically significant (n=3). CONCLUSIONS: Contrary to expectations, the sn-1 and sn-3 derivatives of pAZT were equally effective in reducing HIV replication of HT4-6C cells. This is a surprising result since most cellular phospholipases are thought to be specific for the sn-3 glycerophospholipids. Intact pAZTs have no intrinsic activity against HIV reverse transcriptase (RT). Therefore, the sn-1 pAZT must be degraded in the cell by enzymatic processes which are still uncharacterized before being converted to AZT-triphosphate, the inhibitor of RT.

Keywords: Cell Line Human HIV/*DRUG EFFECTS/PHYSIOLOGY Prodrugs/*PHARMACOLOGY Stereoisomers Virus Replication/*DRUG EFFECTS Zidovudine/*PHARMACOLOGY ABSTRACT
901230
M90C3532

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .